Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Rheumatology (Oxford) ; 60(12): 5595-5600, 2021 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-33590850

RESUMEN

OBJECTIVES: We sought to clarify the presence of radiographic thymus variants using a scoring system, and their association with clinical and immunological features in RA patients. METHODS: A total of 387 RA patients were randomly selected from all patients visiting our department who underwent chest CT scanning, with exclusion of patients with thymoma or thymic cyst, or age < 30 years. Thymus size and attenuation score in axial CT images were quantitatively interpreted and assessed. Associations between immunophenotype data and clinical and serological features were analysed in a subset of patients. RESULTS: Thymic enlargement was found in 76 (19.6%) patients, and a thymus attenuation score ≥ 2 was found in 50 (12.9%) patients. The score was significantly associated with antibodies to ACPA positivity. Thymic enlargement was significantly associated with the proportions of CD4+ effector memory T cells. CONCLUSION: Radiographic thymus variants were frequently observed in RA patients and may reflect an abnormal immune response involved in the pathogenesis of RA.


Asunto(s)
Artritis Reumatoide/diagnóstico , Autoanticuerpos/sangre , Células T de Memoria/inmunología , Timoma/diagnóstico , Timo/diagnóstico por imagen , Neoplasias del Timo/diagnóstico , Tomografía Computarizada por Rayos X/métodos , Anciano , Artritis Reumatoide/sangre , Artritis Reumatoide/complicaciones , Autoanticuerpos/inmunología , Estudios Transversales , Femenino , Citometría de Flujo , Estudios de Seguimiento , Humanos , Inmunidad Celular , Inmunofenotipificación , Masculino , Células T de Memoria/patología , Persona de Mediana Edad , Estudios Retrospectivos , Timoma/complicaciones , Timoma/inmunología , Neoplasias del Timo/complicaciones , Neoplasias del Timo/inmunología
2.
Nat Commun ; 12(1): 430, 2021 01 18.
Artículo en Inglés | MEDLINE | ID: mdl-33462228

RESUMEN

Clinical successes demonstrated by chimeric antigen receptor T-cell immunotherapy have facilitated further development of T-cell immunotherapy against wide variety of diseases. One approach is the development of "off-the-shelf" T-cell sources. Technologies to generate T-cells from pluripotent stem cells (PSCs) may offer platforms to produce "off-the-shelf" and synthetic allogeneic T-cells. However, low differentiation efficiency and poor scalability of current methods may compromise their utilities. Here we show improved differentiation efficiency of T-cells from induced PSCs (iPSCs) derived from an antigen-specific cytotoxic T-cell clone, or from T-cell receptor (TCR)-transduced iPSCs, as starting materials. We additionally describe feeder-free differentiation culture systems that span from iPSC maintenance to T-cell proliferation phases, enabling large-scale regenerated T-cell production. Moreover, simultaneous addition of SDF1α and a p38 inhibitor during T-cell differentiation enhances T-cell commitment. The regenerated T-cells show TCR-dependent functions in vitro and are capable of in vivo anti-tumor activity. This system provides a platform to generate a large number of regenerated T-cells for clinical application and investigate human T-cell differentiation and biology.


Asunto(s)
Técnicas de Cultivo de Célula/métodos , Inmunoterapia Adoptiva/métodos , Células Madre Pluripotentes Inducidas/fisiología , Neoplasias/terapia , Linfocitos T Citotóxicos/trasplante , Animales , Diferenciación Celular/efectos de los fármacos , Línea Celular Tumoral , Quimiocina CXCL12/metabolismo , Medios de Cultivo/metabolismo , Medios de Cultivo/farmacología , Femenino , Humanos , Imidazoles/farmacología , Ratones , Neoplasias/inmunología , Piridinas/farmacología , Receptores Quiméricos de Antígenos/inmunología , Linfocitos T Citotóxicos/inmunología , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Arthritis Res Ther ; 22(1): 153, 2020 06 22.
Artículo en Inglés | MEDLINE | ID: mdl-32571405

RESUMEN

BACKGROUND: The aim of this study was to identify the molecular mechanism of dysregulation of B cell subpopulations of primary Sjögren's syndrome (pSS) at the transcriptome level. METHODS: We enrolled patients with pSS (n = 6) and healthy controls (HCs) (n = 6) in the discovery cohort using microarray and pSS (n = 14) and HCs (n = 12) in the validation cohort using quantitative PCR (qPCR). Peripheral B cells acquired from these subjects were separated by cell sorting into four subsets: CD38-IgD+ (Bm1), CD38+IgD+ (naive B cells), CD38highIgD+ (pre-germinal centre B cells) and CD38±IgD- (memory B cells). We performed differentially expressed gene (DEG) analysis and weighted gene co-expression network analysis (WGCNA). RESULTS: Expression of the long non-coding RNA LINC00487 was significantly upregulated in all B cell subsets, as was that of HLA and interferon (IFN) signature genes. Moreover, the normalized intensity value of LINC00487 significantly correlated with the disease activity score of all pSS B cell subsets. Studies of human B cell lines revealed that the expression of LINC00487 was strongly induced by IFNα. WGCNA revealed six gene clusters associated with the B cell subpopulation of pSS. Further, SOX4 was identified as an inter-module hub gene. CONCLUSION: Our transcriptome analysis revealed key genes involved in the dysregulation of B cell subpopulations associated with pSS. TRIAL REGISTRATION: Not required.


Asunto(s)
Subgrupos de Linfocitos B , Síndrome de Sjögren , Linfocitos B , Perfilación de la Expresión Génica , Centro Germinal , Humanos , Factores de Transcripción SOXC , Síndrome de Sjögren/genética
4.
Cell Stem Cell ; 23(6): 850-858.e4, 2018 12 06.
Artículo en Inglés | MEDLINE | ID: mdl-30449714

RESUMEN

Limited T cell availability and proliferative exhaustion present major barriers to successful T cell-based immunotherapies and may potentially be overcome through the use of "rejuvenated" induced pluripotent stem cells derived from antigen-specific T cells (T-iPSCs). However, strict antigen specificity is essential for safe and efficient T cell immunotherapy. Here, we report that CD8αß T cells from human T-iPSCs lose their antigen specificity through additional rearrangement of the T cell receptor (TCR) α chain gene during the CD4/CD8 double positive stage of in vitro differentiation. CRISPR knockout of a recombinase gene in the T-iPSCs prevented this additional TCR rearrangement. Moreover, when CD8αß T cells were differentiated from monocyte-derived iPSCs that were transduced with an antigen-specific TCR, they showed monoclonal expression of the transduced TCR. TCR-stabilized, regenerated CD8αß T cells effectively inhibit tumor growth in xenograft cancer models. These approaches could contribute to safe and effective regenerative T cell immunotherapies.


Asunto(s)
Antígenos CD8/inmunología , Linfocitos T CD8-positivos/inmunología , Inmunoterapia , Células Madre Pluripotentes Inducidas/inmunología , Neoplasias/terapia , Receptores de Antígenos de Linfocitos T/inmunología , Animales , Humanos , Ratones , Ratones Endogámicos NOD , Ratones SCID , Neoplasias/inmunología , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA